Is Silexion Therapeutics financially healthy?
Not really
Silexion Therapeutics earns only -1,292.4 times its interest bill, which leaves little room.
The numbers behind it
Net debt / EBITDA0.5 years
Cash vs. debt$6M vs. $2M
Current ratio2.4×Short-term assets for each $1 of bills due within a year
Interest coverage-1,292.4×How many times operating profit covers the interest bill
How we decide
We measure debt in years of earnings (net debt / EBITDA): under 1 is very comfortable, 1 to 3 is manageable, above 3 is heavy. A company that earns less than 3 times its interest bill also counts as weak.
More questions about Silexion Therapeutics
Data as of Nov 13, 2026.